U.S. Formulation Development Outsourcing Market Report 2026-2031 | Outsourcing Strategies Support Cost Control and Technical Access; FDA Compliance Remains a Key Market Challenge
Dublin, Aug. 18, 2026 (GLOBE NEWSWIRE) -- The "U.S. Formulation Development Outsourcing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
The report provides market forecasts in USD, detailed segment analysis, competitive intelligence and an assessment of the principal trends shaping the U.S. formulation development outsourcing market.
The U.S. formulation development outsourcing market is projected to grow from USD 9.80 billion in 2025 to USD 10.66 billion in 2026, reaching USD 16.03 billion by 2031. The market is forecast to expand at a compound annual growth rate of 8.5% between 2026 and 2031, supported by increased pharmaceutical outsourcing, growing biologics pipelines, complex injectable products and demand for specialized formulation expertise.
Outsourcing Strategies Support Cost Control and Technical Access
Pharmaceutical and biopharmaceutical companies are increasingly adopting asset-light research and development models and consolidating projects with full-service contract development and manufacturing organizations. In 2025, 73% of FDA approvals involved outsourced active pharmaceutical ingredient manufacturing, compared with 74% in 2024, while 65% relied on outsourced finished-dose manufacturing.
Large pharmaceutical companies are also using risk-sharing agreements incorporating milestone payments and royalty components. Providers with established regulatory records, integrated service capabilities and commercial-scale infrastructure are well positioned to benefit. This consolidation may create higher switching barriers, strengthen pricing power among leading providers and intensify competitive pressure on smaller contract development and manufacturing organizations.
Biologics and Injectable Products Accelerate Market Growth
Biologics represented 45% of FDA approvals in 2025, reinforcing demand for advanced formulation development services across antibody-drug conjugates, monoclonal antibodies and lipid nanoparticle RNA therapies. More than 20% of monoclonal antibody products now use high-concentration formulations, while self-administered subcutaneous delivery continues to gain market traction.
Persistent fill-finish capacity constraints are also increasing the strategic value of domestic sterile manufacturing. Service providers with advanced aseptic filling capabilities, high-concentration formulation expertise and proprietary excipient platforms are expected to capture additional demand from clinical and commercial programs.
FDA Compliance Remains a Key Market Challenge
Stringent FDA chemistry, manufacturing and controls requirements continue to increase development costs and extend project timelines. Between 2020 and 2024, 74% of complete response letters were associated with chemistry, manufacturing and controls or analytical deficiencies. These issues are frequently identified late in the regulatory review process, after substantial development investment.
Novel biologics programs require early comparability planning, qualified secondary suppliers and validated cold-chain logistics. As a result, formulation development outsourcing companies that combine laboratory execution with regulatory advisory services hold a competitive advantage. The FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot program may accelerate eligible breakthrough-designated programs, although its application remains limited to qualifying candidates.
Market Segment Highlights
Formulation development services accounted for 75.69% of the U.S. market in 2025. This share reflects sponsor preference for integrated partnerships that combine analytical development, process development and scale-up activities within a unified quality system.
Preformulation services are forecast to expand at a CAGR of 16.20% through 2031. Growth is being driven by earlier evaluation of viscosity, aggregation risk and excipient compatibility in biologics, antibody-drug conjugates and lipid nanoparticle therapies. Early-stage risk assessment can reduce late-stage reformulation requirements and regulatory disruption.
Injectable and parenteral dosage forms represent the fastest-growing segment, with a projected CAGR of 16.99% through 2031. Expansion is supported by biologics-focused product approvals, limited in-house sterile infrastructure among sponsors and rising demand for high-concentration subcutaneous formulations.
Additional market drivers and constraints covered in the report include:
Key Topics Covered
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Outsourcing to Control Cost and Access Formulation Expertise
4.2.2 Rising Biologics and Injectable Complexity
4.2.3 Oncology and Specialty Pipeline Expansion
4.2.4 Dense U.S. Clinical Trial Activity and Faster Development Timelines
4.2.5 505(B)(2) Reformulation Opportunity Set
4.2.6 Reshoring and Biosecure-Driven Vendor Requalification
4.3 Market Restraints
4.3.1 Stringent FDA CMC and Clinical Trial Compliance
4.3.2 Early-Stage Biotech Funding Volatility
4.3.3 Tariff Exposure Across Excipients and Packaging Inputs
4.3.4 Bridging Study Burden After Formulation Changes
4.4 Value Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Industry Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Service Type
5.1.1 Preformulation Services
5.1.2 Formulation Development Services
5.2 By Dosage Form
5.2.1 Oral
5.2.2 Injectable and Parenteral
5.2.3 Topical and Transdermal
5.2.4 Inhalation and Nasal
5.2.5 Ophthalmic
5.2.6 Buccal, Sublingual, Rectal, and Vaginal
5.3 By Therapeutic Area
5.3.1 Oncology
5.3.2 Infectious Disease
5.3.3 Neurology
5.3.4 Cardiovascular
5.3.5 Respiratory
5.3.6 Hematology
5.3.7 Dermatology
5.3.8 Rare Disease and Genetic Disorders
5.3.9 Autoimmune and Inflammatory Disorders
5.3.10 Others
5.4 By End User
5.4.1 Pharmaceutical and Biopharmaceutical Companies
5.4.2 Government and Academic Institutes
5.4.3 Others
6 Competitive Landscape
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
6.4.1 Adare Pharma Solutions
6.4.2 Alcami Corporation
6.4.3 Bend Bioscience
6.4.4 Cambrex Corporation
6.4.5 Catalent, Inc.
6.4.6 Charles River Laboratories International, Inc.
6.4.7 Curia Global, Inc.
6.4.8 Evonik Health Care
6.4.9 Intertek Group plc
6.4.10 Jubilant HollisterStier LLC
6.4.11 Lonza Group AG
6.4.12 National Resilience, Inc.
6.4.13 PCI Pharma Services
6.4.14 Piramal Pharma Solutions
6.4.15 Quotient Sciences
6.4.16 Recipharm AB
6.4.17 Seran Bioscience
6.4.18 SGS SA
6.4.19 Simtra BioPharma Solutions
6.4.20 Thermo Fisher Scientific Inc. (Patheon)
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/z61m3y
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.